Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.35 USD | +1.85% | +3.77% | +2.41% |
07/03 | Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024 | |
07/03 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Business Summary
Number of employees: 452
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vonoprazan
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Azmi Nabulsi
FOU | Founder | 64 | 09/18/09 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 01/19/01 |
David Socks
FOU | Founder | 49 | 09/18/09 |
Molly Henderson
DFI | Director of Finance/CFO | 54 | 05/22/05 |
Chief Tech/Sci/R&D Officer | 60 | 02/19/02 | |
Eric Sciorilli
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | 06/20/06 | |
Tom Harris
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Fields
BRD | Director/Board Member | 69 | 27/19/27 |
Frank Karbe
BRD | Director/Board Member | 56 | 25/22/25 |
Michael Cola
CHM | Chairman | 64 | 27/19/27 |
James Topper
BRD | Director/Board Member | 62 | 01/18/01 |
David Socks
FOU | Founder | 49 | 09/18/09 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 01/19/01 |
Asit Parikh
BRD | Director/Board Member | 52 | 01/19/01 |
Mark Stenhouse
BRD | Director/Board Member | 57 | 17/20/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,543,101 | 52,883,556 ( 90.33 %) | 19,000 ( 0.0325 %) | 90.33 % |
Company contact information
Phathom Pharmaceuticals, Inc.
100 Campus Drive Suite 102
07932, Florham Park
+
http://www.phathompharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.41% | 537M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- PHAT Stock
- Company Phathom Pharmaceuticals, Inc.